Every lot published · search any lot number before you order

Retatrutide 9 mg: The TRIUMPH-1 Research Arm

The sponsor reported 25.9% average weight reduction at 80 weeks in the TRIUMPH-1 9 mg arm under its efficacy analysis, versus 2.2% with placebo.

Retatrutide 9 mg: The TRIUMPH-1 Research Arm. A Phase 3 target amount. Assigned amount, Trial protocol, Group result. GLP LIFE SCIENCES ยท RESEARCH BRIEF 25 A Phase 3 target amount Dosage research Assigned amountTrial protocolGroup result
A Phase 3 target amount. Illustration for this research brief.

A Phase 3 target amount

The published study design makes the comparison with placebo interpretable within the trial. The difference between the 9 mg and 12 mg headline values is a separate question and needs its own uncertainty and statistical context.

How to interpret the evidence

Use the arm label as a research identifier and retain the analysis definition when summarizing the result.

This series reports assigned research arms for interpreting study results. Retatrutide is investigational, and clinical-trial amounts are not dosing instructions.

Sources